Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization

Mukhina, Marina; Кравцова, Е. Д.; Tsimafeyeu, Ilya; Tjulandin, S. A.; Beliak, Natalia P.; Клещев, М. А.; Орлова, Р. В.

doi:10.17116/patol20238503140

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study, we evaluated 109 patients with locally advanced or metastatic gastric adenocarcinoma [ 13 ]. Overall, FGFR2 expression was detected in 43% cases and amplification in 8% cases [ 14 ]. FGFR2 expression was assessed in the primary tumor as well as in several lymph node metastases from the same patients by immunohistochemistry with three different antibodies (Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8).…”

Section: Challenges Of Fgfr2 Testing In Metastatic Gastric Adenocarci...mentioning

confidence: 99%

Challenges of FGFR2 Testing in Gastric Cancer

Tsimafeyeu,

Raskin

2023

Oncol Rev.

View full text Add to dashboard Cite

Section: Challenges Of Fgfr2 Testing In Metastatic Gastric Adenocarci...mentioning

confidence: 99%

Challenges of FGFR2 Testing in Gastric Cancer

Tsimafeyeu,

Raskin

2023

Oncol Rev.

View full text Add to dashboard Cite

Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co- Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study

Tsimafeyeu,

Musayeva,

Mahmudova

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Immunotherapy is increasingly significant in treating metastatic gastric cancer. This prospective phase 2 study investigates the efficacy and safety of combining nivolumab with chemotherapy in patients with metastatic gastric cancer co-expressing FGFR2 and PD-L1. Methods Eligible patients were aged 18 years or older, with previously untreated HER-2 negative, PD-L1 positive, and FGFR2 positive metastatic gastric adenocarcinoma. Patients received nivolumab (360 mg every 3 weeks) in combination with chemotherapy (CAPOX: capecitabine 1000 mg/m² twice daily on days 1–14 and oxaliplatin 130 mg/m² on day 1, every 3 weeks). Tumor assessments were conducted using RECIST v1.1 every 8 weeks for 48 weeks, then every 12 weeks. The primary endpoint was the 1-year progression-free survival (PFS) rate. Secondary endpoints included median PFS, overall survival (OS), objective response rate (ORR), and grade ≥ 3 adverse events (AEs). Results From June 2022 to October 2023, 194 patients were assessed for eligibility, with 23 patients enrolled and treated. At a median follow-up of 17.3 months, the 1-year PFS rate was 30.4%, with a median PFS of 6.0 months (95% CI, 4.3–7.7). The median OS was 15.1 months (95% CI, 13.2–16.8). The ORR was 21.7%, with one complete response and four partial responses. Grade 3 or higher TRAEs were reported in 34.8% of patients, primarily associated with chemotherapy. No treatment-related deaths occurred. Conclusions While the primary endpoint of improved 1-year PFS rate was not met, the study offers valuable insights into the potential benefits of combining nivolumab with chemotherapy in FGFR2 and PD-L1 co-expressing metastatic gastric cancer. Future research should optimize patient selection, assess combined immunotherapy and targeted anti-FGFR2 therapy, and further investigate the role of subsequent treatments to maximize therapeutic benefits.

show abstract

Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization

Cited by 2 publications

References 18 publications

Challenges of FGFR2 Testing in Gastric Cancer

Challenges of FGFR2 Testing in Gastric Cancer

Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co- Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study

Contact Info

Product

Resources

About